Single-Dose Treatment With Dalbavancin for Acute Bacterial Skin and Skin Structure Infection

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)

Acute bacterial skin and skin structure infections (ABSSSI) are a common disease causing patients to seek treatment through the health care system. With the continued increase of drug-resistant bacterial pathogens, these infections are becoming more difficult to successfully cure. Lipoglycopeptides have unique properties that allow the drug to remain active toward both common and challenging pa...

Dalbavancin for the treatment of acute bacterial skin and skin structure infections.

Dalbavancin is a novel parenteral lipoglycopeptide antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults. Dalbavancin is highly active against common Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Dalbavancin has a prolonged half-life that allows for once weekly dosing. Phase III trials have demons...

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Patients with Diabetes Mellitus

Vancomycin Combined With Clindamycin for the Treatment of Acute Bacterial Skin and Skin-Structure Infections.

BACKGROUND Acute bacterial skin and skin-structure infections (ABSSSIs) are common causes of hospital admissions. These infections are often caused by methicillin-resistant Staphylococcus aureus; therefore, vancomycin remains a commonly used therapy. The purpose of this study was to compare hospital length of stay (LOS) in patients treated with vancomycin monotherapy vs combination therapy with...

Early endpoints for acute bacterial skin and skin structure infections.

In this issue of the journal, Friedland et al. (4) present a retrospective analysis of the two CANVAS trials (3), employing the newer endpoints from the U.S. Food and Drug Administration (FDA) (7). First, they are to be congratulated for having the foresight to include sufficient measurements in their trial to allow the reanalysis even prior to the issuance of the new guidelines. The analysis e...